WO1986000930A1 - Retroviral vaccines and vectors and methods for their construction - Google Patents
Retroviral vaccines and vectors and methods for their construction Download PDFInfo
- Publication number
- WO1986000930A1 WO1986000930A1 PCT/US1985/001352 US8501352W WO8600930A1 WO 1986000930 A1 WO1986000930 A1 WO 1986000930A1 US 8501352 W US8501352 W US 8501352W WO 8600930 A1 WO8600930 A1 WO 8600930A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequences
- dna
- retrovirus
- virus
- encode
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 229960005486 vaccine Drugs 0.000 title claims description 72
- 230000001177 retroviral effect Effects 0.000 title claims description 38
- 239000013598 vector Substances 0.000 title abstract description 44
- 238000010276 construction Methods 0.000 title description 14
- 241000713826 Avian leukosis virus Species 0.000 claims abstract description 141
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 131
- 241000700605 Viruses Species 0.000 claims description 233
- 108020004414 DNA Proteins 0.000 claims description 120
- 239000000427 antigen Substances 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 150000007523 nucleic acids Chemical group 0.000 claims description 17
- 241000271566 Aves Species 0.000 claims description 13
- 108010000912 Egg Proteins Proteins 0.000 claims description 11
- 102000002322 Egg Proteins Human genes 0.000 claims description 11
- 241001213911 Avian retroviruses Species 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 abstract description 55
- 230000009352 congenital transmission Effects 0.000 abstract description 12
- 230000003612 virological effect Effects 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 description 41
- 241000287828 Gallus gallus Species 0.000 description 37
- 235000013330 chicken meat Nutrition 0.000 description 37
- 230000001566 pro-viral effect Effects 0.000 description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 210000003101 oviduct Anatomy 0.000 description 18
- 108020000999 Viral RNA Proteins 0.000 description 17
- 230000003472 neutralizing effect Effects 0.000 description 16
- 230000010076 replication Effects 0.000 description 16
- 102400001093 PAK-2p27 Human genes 0.000 description 15
- 239000003550 marker Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 101800001271 Surface protein Proteins 0.000 description 12
- 230000005540 biological transmission Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000002950 deficient Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 206010021882 Infections and infestations congenital Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000286209 Phasianidae Species 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 102000004389 Ribonucleoproteins Human genes 0.000 description 6
- 108010081734 Ribonucleoproteins Proteins 0.000 description 6
- 101800000385 Transmembrane protein Proteins 0.000 description 6
- 108700004025 env Genes Proteins 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 108700004026 gag Genes Proteins 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 108700004029 pol Genes Proteins 0.000 description 5
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000714165 Feline leukemia virus Species 0.000 description 4
- 208000002979 Influenza in Birds Diseases 0.000 description 4
- 102100034347 Integrase Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010061308 Neonatal infection Diseases 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000004779 membrane envelope Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 241000714266 Bovine leukemia virus Species 0.000 description 3
- 206010062343 Congenital infection Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 101710177291 Gag polyprotein Proteins 0.000 description 3
- 241000712907 Retroviridae Species 0.000 description 3
- 208000005074 Retroviridae Infections Diseases 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 101150030339 env gene Proteins 0.000 description 3
- 244000144992 flock Species 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 101710170658 Endogenous retrovirus group K member 10 Gag polyprotein Proteins 0.000 description 2
- 101710186314 Endogenous retrovirus group K member 21 Gag polyprotein Proteins 0.000 description 2
- 101710162093 Endogenous retrovirus group K member 24 Gag polyprotein Proteins 0.000 description 2
- 101710094596 Endogenous retrovirus group K member 8 Gag polyprotein Proteins 0.000 description 2
- 101710177443 Endogenous retrovirus group K member 9 Gag polyprotein Proteins 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 208000006758 Marek Disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000010359 Newcastle Disease Diseases 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 241000713824 Rous-associated virus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101100118548 Drosophila melanogaster Egfr gene Proteins 0.000 description 1
- 108020004437 Endogenous Retroviruses Proteins 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000714193 Lymphoproliferative disease virus Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 208000005266 avian sarcoma Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Retroviruses and retrovirus vectors that either are or are not shed into eggs and therefore either do or do not undergo congenital transmission, and methods for making them. This invention is based on the discovery that the ability of exogenous avian leukosis viruses to undergo congenital transmission is determined by gag sequences of the viral genome.
Description
RETROVIRAL VACCINES AND VECTORS AND METHODS FOR THEIR CONSTRUCTION
Technical Field
This invention is in the fields of molecular 5 biology and virology and in particular relates to the use of retroviruses for construction of vaccines and expression vectors.
Background Art
The Retroviridae virus family includes viruses
10. which contain an RNA genome and an RNA-dependent DNA polymerase activity (reverse transcriptase) . During their growth cycle, retroviridae, or retroviruses as they are more commonly called, copy their RNA into . proviral DNA. Proviral DNA becomes inserted
15 (integrated) into the chromosomal DNA of the host where it uses the transcriptional and translational •machinery of the host to express viral RNA and proteins. Viruses are released from the cell by budding from the cytoplasmic membrane. Most
20. infections do not kill cells. Rather, infected cells continue to grow and differentiate while continuously producing virus.
The Retroviridae family is divided into three subfamilies: 1) Oncovirinae, which include the oncogenic members and many closely related non- oncogenic viruses; 2) Lentivirinae or the slow
5 viruses; and 3) Spumavirinae or "foamy" viruses, which induce persistent infection but no clinical disease. R. Weiss et al (ed.) , Molecular Biology of Tumor Viruses (2d ed.) RNA Tumor Viruses, 26, Cold Spring Harbor Laboratory (1982) .
10 Viruses in the three subfamilies produce widely varying effects in infected cells but have similar morphological, biochemical and physical properties. Common morphological characteristics include a lipid envelope surrounding an icosahedral protein shell or
15 capsid, which in turn surrounds a ribonucleoprotein (RNP) complex or core (nucleoid) . The capsid and the RNP core as a unit are called a nucleocapsid. Retroviruses have genomic RNA which is a dimer composed of two identical subunits and also have
20. similar protein, lipid, carbohydrate and RNA compositions.
The RNA genome of all replication-competent retroviruses (those capable of producing fully infectious progeny) contains three genes which
25 encode viral structural proteins. The gag gene encodes the internal structural (nucleocapsid) proteins; the pol gene encodes the RNA-directed DNA polymerase (reverse transcriptase) ; and the env gene encodes the envelope glycoproteins of the virion.
30 The genetic organization of all retroviruses is similar to that of avian leukosis virus (ALVs) . The proteins encoded by the gag, pol and env genes of
members of the different retroviral families differ in size but serve similar functions.
If a genome lacks any one of these three genes, the virus in which it occurs is defective for replication. This defect may be circumvented if cells infected with a defective virus are coinfected or superinfected with a related virus that can serve as a helper virus. A helper virus provides proteins required by the defective virus to undergo an infectious life cycle. The proteins provided by the helper virus confer on the particles containing the genome of the defective virus the antigenic characteristics as well as the host range and growth restrictions of the helper virus. In addition to the gag, pol, and env genes, all retroviral genomes, whether replication competent or defective, contain sequences encoding signals essential to the reverse transcription of viral RNA into proviral DNA; the integration of proviral DNA into host chromosomal DNA; the transcription of viral RNA and RNA from integrated proviral DNA; the translation of viral RNA into protein; and the packaging of viral RNA into virions. These sequences act only on the DNA or RNA in which they are contained and are therefore referred to as cis-acting signals. Cis-acting signals that are essential for an RNA to be able to undergo a retrovirus life cycle are found in a short repeat sequence (R) located at both the 5* and the 3' ends of viral RNA; in sequences that are unique to the 5' (U5) and the 3' (U3) ends of viral RNA; and in sequences lying immediately adjacent to U5 and U3.
In infected cells, viral RNA is reverse transcribed by the RNA-dependent DNA polymerase of the virus into proviral DNA. Proviral DNA is found in both integrated and unintegrated forms in infected cells. The unintegrated forms may be linear molecules or closed circular molecules. Integrated as well as unintegrated proviral DNAs have similar genetic organizations. In proviral DNA the R, U5, and U3 sequences of viral RNA are long terminal repeat (LTR) sequences that flank the gag, pol, and env genes. The LTRs, as well as immediately adjacent sequences, contain cis-acting signals that are essential for an RNA to be able to undergo a retrovirus life cycle. The gag, pol and env sequences of the retro¬ viral genome each encodes highly specific protein products. The gag gene product of ALVs is a polyprotein (approximately 65,000-80,000 daltons) In the avian retroviruses, the gag polyprotein is cleaved to produce four major core or capsid proteins: pl9, pl2, p27 and pl5. pl9 occurs in association with viral RNA and the lipid envelope and may have a role in viral mRNA metabolism. pl2 occurs in association with viral RNA and is appar- ently the major protein of the viral RNP complex. p27 is thought to form the core shell or capsid which surrounds the RNP and lies between the RNP and the lipid envelope. pl5 is a protease that cleaves the pl9, pl2, and p27 proteins from the gag-polyprotein. In addition, plO, a minor nongly- cosylated polypeptide, is encoded by gag and is thought to reside on or within the viral envelope.
The pol gene product is the viral RNAdependent DNA polymerase responsible for the synthesis of proviral DNA on the viral RNA template. The gag and pol genes, as well as their protein products, are highly conserved among related strains of viruses. The env gene encodes the envelope or surface gl coproteins of the virion. Related groups of retroviruses are classified into subgroups according to host range, serum neutralization, and interference patterns. Each of these properties is determined by the env-gene products. In ALVs, an env-gene polyprotein is cleaved to produce two envelope glycoproteins, gp85 and gp37. gp85 sequences contain the antigens that determine host range and elicit the production of neutralizing serum by the infected host. gp37 serves to anchor gp85 in the viral membrane. ALVs have been classi¬ fied into 5 different subgroups, labelled A through E, on the basis of determinants found in gp85. Retroviruses are distributed widely among vertebrates and may also occur in some inverte¬ brates. Orders from which retroviruses have been isolated include Gallifor es (chickens, pheasants, turkeys); Rodentia (rats, mice, hamsters, guinea pigs) , Carnivora (cats) ; Artiodactyla (cattle, deer, pig); and Primates (monkeys, apes, humans). Many of these orders contain more than one family of retroviruses. For example, avian retroviruses fall into four groups, which include: the avian sarcoma and leukosis viruses of chickens (ALVs) ; the pheasant viruses of pheasant and quail; the reticuloenclotheliosis virus of turkeys; and the lymphoproliferative disease viruses of turkeys.
Most families of retrovirususes exist and are transmitted by endogenous as well as exogenous viruses. Endogenous retroviruses are retroviruses whose proviral DNA has become inserted into the germ line DNA of their host. These viruses are endogenous to their host in the sense that they have become part of the genetic information of their host. Although endogenous viruses can be transmitted by infections, the most frequent route for the transmission of these viruses is through the proviral DNA present in gametes.
Exogenous retroviruses are viruses whose genetic information is being transmitted exclusively by virus infections. The vast majority of these infections do not result in integration of proviral DNA into the DNA of gametes. Thus these infections are not transmitted by the gametes of their hosts. The structure of endogenous proviruses is the same as that of proviruses that result from infec- tion by an endogenous or exogenous virus. However, endogenous members of a group of retroviruses frequently have genes or control signals that encode slightly different biological properties from those found in exogenous ALVs. These differences in homologous sequences determine differences in the disease potential and transmission of endogenous and exogenous virus infections.
Exogenous viruses are associated with a wide spectrum of diseases which vary in incidence and time of onset. For example, exogenous ALVs cause B-cell lymphomas, erythroid and myeloid leukemias, hemangiomas, and osteopetrosis. In most instances, only a fraction of the infected birds develop
disease. For example, in the case of erythroblastosis, disease occurs only if a provirus inserts into or becomes a transducing agent for the host gene c-erbB. However, even if overt disease does not develop; infected birds, especially those that become persistently viremic, tend to lag behind uninfected controls in weight gain and egg production.
In contrast, infections by most endogenous viruses tend to be benign. When endogenous ALVs are introduced back into chickens as infections, no disease is observed and infected chickens appear to undergo normal weight gain and egg production.
In order to survive, exogenous viruses must undergo efficient transmission from infected to uninfected hosts. In most instances, .exogenous viruses have evolved so that they undergo highly efficient transmission by congenital and neo-natal infections. Congenital and neonatal infections, because they occur in hosts whose immune systems are not fully developed, tend to establish viremias that persist throughout the lives of the infected animal. For most exogenous viruses, congenital and neonatal infections provide the major reservoirs of virus in infected populations. Thus, control of congenital infections is key to the erradication of a retrovirus.
For example, ALVs of exogenous origin replicate throughout the reproductive tract of the hen, with large numbers of budding virus occurring in the magnum- or albumen secreting region of the oviduct. The developing embryos become infected and hatch into chickens whose immune system recognizes the
virus as self. Because the ALV antigens are recognized as self, antibodies against ALVs are not made. A persistent viremia is established and each generation of viremic hens produces viremic off- spring.
Domesticated animals that are raised in flocks or herds (e.g., poultry, cattle, sheep) are partic¬ ularly vulnerable to retrovirus infections. Centralized breeding programs and crowded conditions of commercial farms favor the persistence and spread of retrovirus infections. For example, avian leukosis virus infections in laying hens are a commercial problem because they increase mortality and decrease egg production. In addition, viremic hens shed virus into their eggs and therefore produce viremic progeny whose health and egg production are compromised by the infection.
The present approach by cattle, sheep and poultry farmers to the control of retrovirus infections is to eliminate viremic individuals from the breeding population. Although this approach has proved effective when progeny of virus-free individuals have .been reared in isolation (e.g. , in research facilities) , it is far less effective when used on the farm. On the farm, identification of shedders may not be adequate and progeny of virus- free individuals become infected because they are raised in proximity to infected adults. Thus the infections persists and continue to be transmitted from one animal to another.
In the poultry industry, efforts have been made to control ALV infections by using field strains of ALVs as live vaccines. For example, Dutch
researchers have controlled ALV infections by eliminating shedders from their breeding population, rearing virus-free chicks in isolation until two months of age and then vaccinating the two-month old chicks with a mixture of subgroup A and subgroup B ALVs (RAV-1 and RAV-2) . After this protocol was repeated for three generations, the flocks tested appeared to be free of ALV-associated disease. B. H. Rispens et al., "A method for the control of lymphoid leukosis in chickens," Journal of the
National Cancer Institute 57: 1151-1156. (1976). The success of the Dutch researchers is due to the elimination of infected individuals from the breeding population, the availability of facilities to rear chicks in isolation, and the vaccination of birds at an age when the immune response to the infection curtails both the pathogenic potential of the virus as well as the infection of the oviduct and subsequent congenital transmission of the unattenuated vaccine virus.
The approach of the Dutch, however, is not suitable to commercial application because of the need for rigorous screening for hens that are shedding virus and for the isolation of chicks. Furthermore, the currently used method of control¬ ling ALV infections in the U.S. —elimination of shedders— is inefficient, because it fails to identify many viremic hens, and expensive because of the tests required to identify shedders and the requirement that shedders be eliminated.
Summary of the Invention
This invention arises from the Applicant's
discovery that the ability of exogenous avian leukosis viruses to undergo congenital transmission is determined by the gag sequences of the viral genome. A direct correlation exists between the presence of sequences encoding the gag-encoded p27 protein of exogenous ALVs and the ability of a virus to be shed into egg albumen. That is, recombinants of endogenous and exogenous ALVs with the exogenous p27 marker of the exogenous parent undergo efficient replication in the oviduct and shedding into eggs, but those with the analogous marker (p27°) from the endogenous parent do not.
This knowledge has made it possible to con¬ struct retroviruses and retrovirus vectors that either are or are not shed into eggs" and therefore either do or do not undergo congenital transmission. Retroviruses and retrovirus vectors constructed for use as vaccine viruses would be attenuated viruses that contain the gag sequences of an endogenous retrovirus and thus are not shed.into the egg.
Therefore, congenital infections do not occur. On the other hand, retroviruses constructed according to the method of this invention which are to be used for obtaining desired proteins in eggs contain the gag sequences of an exogenous retrovirus. As a result, the virus infects the oviduct and the products of the vector virus are shed into the egg.
In one embodiment of this invention, benign (nonpathogenic) but immunizing vaccines against ALVs are made. The vaccine viruses are constructed from nucleic acid sequences which include sequences from endogenous and exogenous ALVs. The vaccine viruses
are constructed so as to express gp85-host range determinants of the exogenous virus or viruses against which the vaccine is directed. These host range or type specific determinants encode antigens which elicit an immune response to the virus. The vaccine viruses have the gag sequences of an endogenous ALV. The gag sequences of endogenous ALVs ensure that the vaccine virus will not undergo congenital infections or transmission. The vaccine viruses have pol and LTR sequences from ALVs of endogenous or exogenous origin and may have sequences not found in endogenous or exogenous ALVs.
The DNAs which contain sequences from endoge¬ nous and exogenous ALVs are used as vaccines by either directly inoculating DNA into chickens Fung et al Proceedings of the National Academy of Sciences, J3):353-357 (1983) or by inoculating virus expressing the DNA following transfection of cul¬ tured cells Graham et al. Virology, 52:456-467, (1973) as modified by Loyter et al. Proceedings of the National Academy of Sciences, 79:422-426 (1982) . The vaccine of this invention is unique in that it evokes the immune response necessary to immunize the chicken against an exogenous ALV infection but produces no pathogenic effects in the recipient and is not shed into the egg. As a result, adults will be immunized against an exogenous ALV infections and progeny of vaccinated hens will not be tolerized to the exogenous ALV. In another embodiment of the method of this invention, vaccines for viruses other than retroviruses are made. In this embodiment, the vaccine virus consists of a vector virus and a
helper virus. The vector virus is a replication defective retrovirus that expresses antigens encoded in the nucleic acid sequences of another virus. That is, it contains sequences encoding determinants that stimulate the production of neutralizing serum to the virus against which an immune response is desired. The vector virus includes sequences encoding the desired antigens as well as sequences from endogenous and'exogenous ALVs. The helper virus is a retrovirus which provides the necessary proteins for the replication of the vector virus. The helper virus is a benign virus made from nucleic acid sequences which include those of endogenous and exogenous ALVs. In particular it contains the gag sequences of endogenous virus that restrict the replication of the vector as well as helper virus in the oviduct.
Virus expressed by cultured cells that have been contransfeeted with vector and helper DNAs are used as inocula for vaccination. A mixture of the vector and helper DNAs may also be used as an inocula. The vaccine made according to this method immunizes against a virus other than a retrovirus but because the helper virus does not replicate in the oviduct, progeny of vaccinated hosts will not be tolerized to antigens expressed by the vector or helper components of the vaccine.
In still another embodiment of the method of this invention, retrovirus stocks that serve as expression vectors for specific proteins are made. These expression vectors make it possible to have a desired protein secreted at high levels into the eggs of infected hens. The virus stock consists of
a vector virus and a helper virus. The vector virus is a replication defective virus which expresses the protein to be secreted into egg albumen under the transcriptional control of sequences that normally control the transcription of chicken egg white protein. The vector is made from sequences that include: 1) sequences encoding the desired protein, 2) sequences containing control signs for egg white protein production, and 3) sequences from endogenous and exogenous ALVs. The helper virus is a retrovirus which provides the proteins necessary for the vector virus to establish efficient infection of the oviduct. It is made from sequences that include those from endogenous and exogenous retroviruses. In particular, the helper contains the gag sequences from an exogenous retrovirus that ensure efficient infection of the oviduct by the vector virus. Virus expressed by cultured cells that have been contransfected with vector and helper DNAs are used as inocula. The virus stocks in this embodiment are unique in that they result in proteins of commercial value, such as hormones, blood clotting factors and plasma proteins being secreted into the eggs. The secreted protein is subsequently harvested from the egg.
Brief Description of the Figures
Figure la is a simplified representation of the viral RNA of an ALV; Figure lb is a simplified representation of a linear form of proviral DNA of an ALV.
Figure 2 is a simplified representation of DNA sequences used in making a vaccine for ALVs
according to this invention, wherein: Figure 2a is a simplified representation of the DNA of the endogenous ALV, RAV-0; Figure 2b is a simplified representation of the DNA of the exogenous ALV, RAV-1; and Figure 2c is a simplified representation of the DNA of a construct used as a vaccine or for the recovery of a vaccine virus.
Figure 3 is a simplified representation of DNAs used in making retroviral vaccines for viruses other than retroviruses according to this invention, wherein: Figure 3a is a simplified representation of a DNA sequence that encodes an antigen (or antigens) of a virus other then a retrovirus. Figure 3b is a simplified representation of the DNA of a helper virus that has been made from sequences present in endogenous and exogenous ALVs; and Figure 3c is a simplified representation of the proviral DNA of a retroviral vector that expresses the antigens of 3a. Figure 4 is a simplified representation of the DNAs used in making a retrovirus stock that results in a desired protein being secreted into eggs of infected hens according to this invention, wherein: Figure 4a is a simplified representation of a DNA sequence that controls the expression of ovalbumin; Figure 4b is a simplified representation of a DNA sequence that encodes the protein to be secreted into egg albumen; Figure 4c is a simplified representation of the proviral DNA of a helper virus, made from sequences found in endogenous and exogenous ALVs;and Figure 4d is a simplified representation of a retroviral vector that expresses the protein encoded in the DNA sequence shown in
Figure 4b under the transcriptional control of sequences shown in 4a.
Best Mode of Carrying Out the Invention
The ability to make a retrovirus which is or is not transmitted by congenital infection is based on the discovery that the shedding of ALVs into the eggs of laying hens is determined by the gag sequences of the viral genome. A direct correlation has been shown to exist between the presence of the gag-encoded p27 protein of exogenous ALVs and the ability of a virus to be shed into egg albumen. Viruses with the exogenous p27 protein were shown to undergo efficient shedding into eggs, whereas viruses with the endogenous p27° protein were shown not to be shed into eggs.
This discovery is the result of the examination of the shedding into eggs of eight recombinants of endogenous and exogenous ALVs. This examination was carried out in an effort to define the region of the genome of endogenous viruses which restricted the shedding of endogenous ALVs into the eggs of K28 hens.
K28 is a line of chickens bred for suscepti¬ bility to endogenous virus infections. Endogenous viruses replicate well in K28 chickens, establishing levels of viremia comparable to levels* observed in K28 chickens infected with exogenous ALVs. K28 hens infected with exogenous ALVs shed high titers of virus into egg albumen but those infected with the endogenous virus RAV-0 did not shed virus into egg albumen.
The reco binants examined included: 1) four viruses (RAV-60s) which were generated during growth of exogenous viruses in cells that expressed replication-defective endogenous viruses; two viruses (NTRE-2 and NTRE-7)' which were generated during mixed infection of cells with an exogenous virus and an endogenous virus; and three viruses (recALVW 44,45 and recALVBr22) which were recovered from DNA constructions that recombined specific fragments of molecularly cloned proviral DNAs.
Tests for the transmission into eggs of the recombinant viruses were performed on eggs layed by viremic K28 hens. The presence of virus in egg albumen was assayed by incubating albumen with antiserum to the group specific antigens of ALVs and then testing for complement fixation..
Five of the eight recombinant viruses underwent efficient egg transmission; whereas, three did not. The genomes of the recombinants contained a number of markers for sequences from their endogenous and exogenous parents. Most of the markers were oligonucleotides that were diagnostic for the RNA of the endogenous or the exogenous parents. The host range of the recombinant was used as a marker for gp85 sequences. (gp85 sequences contain the type specific antigens which determine the host range of a retrovirus.) The electrophoretic mobility of the p27 protein was used as a marker for the sequence which encodes it. All eight of the recombinants had the subgroup Ξ host range of their endogenous parent and U- sequences from their exogenous parent. Thus, sequences encoding host range and U_ do not
determine whether ALVs undergo efficient congenital transmission. In addition, markers in the U5, pl9, and gp37 sequence from the endogenous and exogenous parents did. not correlate with the ability of the recombinant to undergo congenital transmission.
Thus, these sequences do not play a role in congen¬ ital transmission.
However, each of the five recombinants which underwent efficient shedding into eggs had the p27 marker of the exogenous parent. Conversely, the three recombinants which did not undergo efficient shedding had the p27° marker of the endogenous parent. Thus, there is a direct correlation between the presence of the p27 marker of exogenous ALVs and the ability to be shed into egg albumen.
The complement fixation assay for gs antigens is a relatively insensitive assay for ALVs. Therefore, the restriction on the congenital transmission of endogenous ALVs was examined by culturing embryonic progeny of hens infected with RAV-0 or NTRE-7. RAV-0 is the prototype endogenous virus. NTRE-7 is a non-transmitted recombinant that has the high growth potential of exogenous ALVs. Cultured cells were assayed for virus at one, two and three weeks of culture. Since, in this period of time, even a single infectious unit of virus would have had ample time to spread throughout the culture and thus score in the assays for virus, the restriction on the ability of RAV-0 and NTRE-7 to be passed by congenital infection in K28 chickens is absolute. Nucleic acid sequences encoding viruses may be made from (constructed) sequences found in endogenous or exogenous viruses. The sequences can
be obtained from viral RNA or DNA. Synthesized DNA sequences not occurring in viruses may also be used.
I. Vaccine Viruses for Retroviruses
Based upon the aforementioned findings, attenuated viruses can be made for the control of exogenous ALV infections. The vaccine viruses, which are benign but immunizing, can be made from the DNAs of endogenous and exogenous ALVs. The vaccines contain DNAs or ALVs expressed by the DNA following transfection of cultured cells with the DNAs. The DNAs contain sequences that encode antigens of an exogenous ALV and the gag sequences of an endogenous ALV, such as RAV-0. The gag sequences of RAV-0 restrict the replication of the vaccine virus in oviduct tissue and ensure that the vaccine virus is not transmitted to the progeny of vaccinated hens by congenital infections. If congenital infections were not controlled, the vaccine virus would be transmitted to the developing chick, which would recognize it as "normal" and fail to respond the antigens expressed by the vaccine. Use of the virus as a vaccine is superior to the use of a field strain of an ALV as a vaccine because the constructed virus is benign, and does not tolerize progeny of the vaccinated adult to the vaccine.
Figure 2 illustrates the construction of such a vaccine. Figures 2a and 2b are simplified representations of DNA sequences used in making the vaccine. pRAV-0 (Figure 2a) and pRAV-1 (Figure 2b) represent, respectively, the DNAs of RAV-0 (an
endogenous retrovirus) and RAV-1 (an exogenous ALV of subgroup A) . pA (Figure 2c) represents DNA of a construct used as a vaccine or for the-recovery of a virus for use as a vaccine. pA is made by linking' DNA sequences comprising the DNA of pRAV-0 and pRAV-1. The sequences used in pA may be synthesized or may be generated from proviral DNAs by the use of nucleases. Where necessary, DNA fragments are amplified by growth in plasmid vectors. pA 'contains gag and pol sequences of pRAV-0 and env sequences of pRAV-1. The pRAV-1 env sequences which are substituted for the pRAV-0 env sequences encode the type specific determinants of the gp85 of pRAV-1. The type specific antigens of gp85 determine host range and elicit an immunizing response to infections by subgroup A viruses, gag sequences of RAV-0 ensure restricted replication in oviduct tissue. Because viral replication in the oviduct is restricted, the vaccine virus will not be shed into eggs and the progeny of vaccinated hens will not be tolerized to the vaccine virus, pol sequences from pRAV-0 are used because RAV-0 is a benign virus. LTR sequences of RAV-0 that encode an intermediate growth potential have been used in pA. Construction of a vaccine for subgroup A ALVs is described in detail in Example 3. The vaccine constructed as described in the example was shown to have most of the gag and all of the pol sequences of the benign RAV-0 virus and the env and the LTR sequences of the subgroup A RAV-1 virus.
Sequences that encode higher growth potentials could be used instead of those from RAV-0. ALV vaccines with sequences encoding other antigenic determinants can be made using sequences encoding
the host range of other ALVs such as Resistance Inducing Factors (RIF) , helpers for laboratory strains of acute sarcoma and leukemia viruses (e.g. Rous Associated Viruses (RAVs)) and transformation defective derivatives of acute transforming viruses (e.g., td Praque Rous Sarcoma Virus (tdPrRSV)) .
Virus for the vaccination of chickens is expressed by DNA following cleavage of the DNA from vector plasmids and transfection of cultures of eukaryotic cells, such as turkey or chicken.
Viruses recovered from the transfected cultures are propagated by infection of eukaryotic cells, such as turkey, chicken or quail. Chickens can also be vaccinated by inoculation of the DNA. The method of this invention can also be used to made vaccine viruses from retroviruses other than avian retroviruses. For example, endogenous and exogenous feline leukemia viruses could be used for the construction of a vaccine for feline leukemia virus. The endogenous viruses used can be pro¬ viruses encoding replication competent as well as replication defective feline leukemia viruses. The exogenous viruses, against which immunization is desired, are field strains of feline leukemia viruses and helper viruses for the acute leukemia and sarcoma-inducing viruses of cats, gag sequence of the endogenous virus may restrict replication in the reproductive as well as mammary and salivary tissues; which are important sources of virus for the congenital and neonatal infection of new born cats. In this embodiment one would not necessarily be limited to using sequences from the same family of retroviruses or sequences originally observed in retroviruses for the construction of vaccine
viruses. For example, a suitable vaccine for bovine leukemia viruses might be constructed with sequences found in bovine leukemia viruses as well as gag sequences found in feline or murine leukemia viruses. Or, gag sequences observed in bovine leukemia viruses could be appropriately modified in vitro so that these sequences, when used in con¬ structs would provide benign yet immunizing infec¬ tions that are not readily transmitted to embryos or neonates.
II. Vaccine Viruses for Viruses Other Than Retroviruses
In another preferred embodiment of this inven¬ tion, retroviruses are used to make retroviral vaccines for viruses other than retroviruses. The vaccines consist of two viral components: a vector virus and a helper virus. The vector virus is a replication defective retrovirus which expresses antigenic determinants of a virus other than a retrovirus. The helper virus is a retrovirus that provides the necessary proteins for the replication of the vector virus. Both vector and help viruses are made from nucleic acid sequences (e.g. DNA) . Avian diseases for which immunizing retrovi- ruses could be made include: Marek's disease, for which the viral protein with immunizing determinants are envelope antigens; and avian influenza or fowl plague and Newcastle Disease, for which the viral protein with immunizing determinants is hemag- glutinin. Marek's disease is caused by a herpes virus, avian influenza or fowl plague by ortho- myxoviruses, and Newcastle Disease by a para- myxovirus.
Figure 3 illustrates an embodiment of this invention. pX (Figure 3a) is a sequence that encodes an antigen or antigens which elicit an immune response to the virus from which pX was taken. The size and genetic content of pX depend upon the antigens which it encodes. pA (Figure 3b) is an example of a helper virus used to make as well as the propagation of vaccines for viruses other than retroviruses. pA is a representation of the DNA of an ALV made from RAV-0 and RAV-1 sequences (see Figure 2) . It has gag and pol sequences from RAV-0 and env sequences from RAV-1. The gag sequences from RAV-0 restrict the replication of the virus encoded in the oviduct and as a result, the virus encoded in pA as well as any vectors for which it is a helper will not be shed into eggs. Therefore, adults will be immunized by the vaccine but progeny of vaccinated hens will not be tolerized to antigens expressed by the vaccine pol sequences from RAV-0 are retained because RAV-0 is a benign virus. The env sequences from RAV-1 encode a subgroup A host range. This host range ensures infection and therefore vaccina¬ tion of the vast majority of egg laying stocks of chickens. gp85 sequences encoding other host ranges, for example that of RAV-2 which encodes subgroup B host range, could be used. pA has the LTR sequences of RAV-0 that encode an intermediate level of replication. LTR sequences that encode higher growth potentials could also be used to construct vaccine virus.
• pAX (Figure 3c) is a representation of a DNA of a retroviral vector that expresses sequences in pX. As shown, pAX expresses antigens from only one DNA sequence, those in pX. pAX could be constructed
with DNA sequences expressing more than one antigen. The retroviral sequences in pAX have cis-acting signals for the reverse transcription of viral RNA into proviral DNA; the integration of proviral DNA into chromosomal DNA; the transcription of RNA from proviral DNA; and the packaging of transcripts of viral RNA into infectious virions.
Other sequences in pAX are those that facili¬ tate the constructions while ensuring expression of the antigens encoded in pX and the transmission of the RNA expressed by the vector as a retrovirus. pAX is made by linking pX sequences with DNA sequences of a helper virus such as that represented in pA. In pAX, pX sequences may be added in the same or the opposite transcriptional orientation to proviral sequences. Junctions of pA and pX sequences ensure expression of the antigens expressed in pX. Junctions also ensure that RNAs expressed by pAX undergo a retrovirus life cycle. DNAs other than those in pA and pAX may be used to make pAX.
Virus is recovered from DNA by cleavage of construct DNAs from plasmid vectors and the transfection of cultures of appropriate eukaryotic cells (e.g., turkey, chicken) with DNA. Vector DNAs are co-transfected with helper DNAs. Once a virus stock is obtained it is further replicated by infection of cultured cells. Animals can also be vaccinated by direct innoculation of a mixture of the vector and helper DNAs.
III. Retroviruses to be Used as Expression Vectors In another preferred embodiment of this invention, retrovirus stocks are made that secrete
high levels of a desired protein into eggs. These stocks consist of an expression vector and a helper virus. The expression vector is made to maximize the secretion into eggs of a protein or proteins encoded in the vector. The' helper virus is made so as to ensure an efficient yet non-pathogenic infection of the oviduct by the vector.
Figure 4 is a representation of the DNAs to be used in making a retrovirus stock which results in the secretion of high levels of a protein into the eggs of infected hens. The vector virus is a replication defective retrovirus which contains one or more genes whose products are to be secreted into the egg. The protein to be secreted into egg albumen is under the transcriptional control of sequences that normally control the transcription of a chicken egg white protein.
Products which could be expressed by the vector viruses include hypothalmic and pituitary hormones (e.g., thyroid releasing hormone', somatostatin) ; blood clotting factors (e.g.. Factor VIII); plasma proteins (e.g., human serum albumin); peptide growth hormones (e.g., interleukins 1,2,3, insulin); anti-viral proteins (e.g., interferon) ; and secreted proteins (e.g., lipase) .
The helper virus is a retrovirus which provides the necessary proteins for the vector virus to establish an efficient infection of the oviduct. The helper virus has the gag gene of an exogenous retrovirus, such as RAV-1, which ensures infection of the oviduct. Pol, env and LTR sequences of the helper virus are derived from endogenous retrovirus sequences such as those of RAV-0, or from exogenous
retroviruses. They ensure that the infection of the host chicken and oviduct is efficient but non-pathogenic. pOV (Figure 4a) represents a DNA sequence that contains signals for the expression of an egg white protein (e.g., ovalbumin) . The pol sequences ensure high levels of synthesis of pY in the oviduct and and that the RNA of the pCOVY vector is able to undergo a retrovirus life cycle. pY (Figure 4b) represents sequences that encode the protein to be secreted into egg albumen. The sequence content of pY will depend upon the protein it encodes. pC (Figure 4c) represents helper virus used to make as well as propagate vectors containing pY sequences under the transcriptional control of pOV. pC is DNA of an ALV made from RAV-0 and RAV-1 sequences. pC has gag sequences from RAV-1 that ensure efficient infection of oviduct tissue. It also has pol sequences from the benign endogenous virus RAV-0. Env sequences are those from RAV-1 that encode a subgroup A host range. If other host ranges are desired, appropriate env sequences from other subgroups of ALVs can be used. pC has the LTR sequences of RAV-0 that encode an intermediate growth potential. Sequences that encode higher growth potentials could also be used in the construction of pC. pC is made by linking sequences from RAV-0 and RAV-1 DNAs. Other DNAs could be used. pCOVY (Figure 4d) represents a retroviral vector made from pC, pOV, and pY. This vector expresses the protein encoded in pY under the
transcriptional control of sequences in pOV. The sequences from pOV are those that give high levels of expression of proteins encoded in pY yet allow the RNA encoded by pCOVY to undergo a retrovirus life cycle. The expression of Y by pOV is such that it does not interfere with egg production by infected hens. pCOVY is made by the linking of sequences from pOV, pY and pC. pOV and pY may be inserted into proviral DNA in the same or the opposite transcrip¬ tional orientation as proviral DNA. The retroviral sequences in pCOVY are those that contain cis-acting signals for the reverse transcription of viral RNA into proviral DNA; the integration of proviral DNA into host chromosomal DNA; the transcription of proviral DNA into RNA; and the packaging of proviral RNA into infectious virions. Other retroviral sequences in pCOVY include those that facilitate the preparation of the constructions while ensuring high levels of pY expression under the control of pOV sequences and the transmission of vector RNAs in infectious virions. Other DNAs may be used to make pCOVY.
Virus stocks are produced by cleaving helper and vector DNAs from plasmid vectors and co-transfecting appropriate cultures of eukaryotic cells, such as turkey, chicken. Once a virus stock is obtained it is propagated by infection of appropriate cultures of eukaryotic cells. The method of this invention is not limited in application to retroviruses of avian origin. Retroviruses are found widely in nature and it is anticipated that retroviruses of feline, bovine and
murine origin, among others, can be used to con¬ struct retroviruses useful as vaccines and expres¬ sion vectors.
Examples
Example 1: Congenital Transmission of Exogenous
Avian Leukosis Viruses But Not Endogenous Avian
Leukosis Viruses in K28 Chickens.
K28 chickens were intravenously inoculated at 1 day of age with approximately 1 x 10 infectious units (i.u.) of one of the following viruses as shown:
Subgroup of Number of gs +albumens/
Virus Virus hens albumens tested
Exogenous R RAAVV--11 AA 2 2 7/7 pRAV-1 1 4/4 tdPr-B B 2 4/4 Endogenous
RAV-0 E 27 0/81 pRAV-0 2 0/15 pRAV-1 is virus recovered from RAV-1 proviral DNA cloned into the Sad site of pBr322. pRAV-0 is virus recovered from RAV-0 proviral DNA cloned into the Sail site of pBR322. Albumens were collected from freshly layed eggs of the K28 hens which had been inoculated as above. Sera were collected from laying hens and virus was measured by assaying for the amount of particulate RNA-directed DNA polymerase. ALV group specific antigens (gs) were determined by assaying for complement fixation in reactions of egg albumen and
antiserum to gs antigens. The gs antigens in egg albumen had the electrophoretic mobilities that are characteristic of the viral proteins (p27, pl9, pl5, pl2). As indicated by the number of gs+ albumens found (gs+ albumens/albumens tested) , exogenous avian leukosis viruses were congenitally transmitted, but endogenous were not.
Example 2: Congenital Transmission of Recombinants of Exogenous and Endogenous Avian Leukosis Viruses
K28 chickens were intravenously inoculated at 1 day of age with one of the following recombinants of exogenous and endogenous avian leukosis viruses:
Number of gs + albumens/
Recombinant henε allDumens tested NY201RAV-60 5 20/20
NY203RAV-60 1 4/4
NY202RAV-60 3 0/14
NY204RAV-60 1 4/4
NTRE-2 3 12/12
NTRE-7 5 0/15 recALV F44, 45 3 0/11 recALVB22 4 10/10
Albumens were collected and assayed as in Example 1. Five of the eight recombinants underwent efficient egg transmission (NY201RAV-60; NY203RAV-60; NY204RAV-60; NTRE-2; recALVBr22) and three did not (NY202RAV-60; NTRE-7; recALVWF44,45) . The recombinants were grouped according to whether they were shed into egg albumen or not.
Their genomes were then scored for markers for their endogenous and exogenous parents. Most markers were oligonucleotides that were diagnostic for the endogenous or the exogenous parents of the recombinants (i.e., markers' for sequences in U5, pi9, pol, gp37 and U_) . The electrophoretic mobil¬ ity of the p27 protein was used as a marker for p27 and p27°. The subgroup of the recombinant was used as the marker for gp85. No markers were present for the pl2 and pl5 capsid proteins. (N, marker from endogenous parent; X, marker from exogenous parent) .
Recombinant Virus U5. pl9 p27 pol gp85 gp37 ___
Transmitted
NY201RAV-60 X ' N+X X X N X - X
NY203RAV-60 X X X X N X X
NY204RAV-60 X N+X X N N X X
NTRE-2 N N X X N N+X X r'ecALVBr22 N N X X N X X
Non-Transmitted
NY202RAV-60 X N+X N X N X X
NTRE-7 N N N N N N X recALVWF44,45 N N N N N X X
All of the recombinants had the subgroup E host range of their endogenous parent and U« sequence from their exogenous parent. Thus gp85 sequences that determine host range and U- sequences of ALVs do not determine whether ALVs undergo efficient congenital transmission. U5, pl9 and gp37 sequences also do not appear to play a key role in congenital transmission.
There was, however, a direct correlation between the presence of the p27 marker of exogenous ALVs and the ability of a recombinant to be shed into egg albumen. The five recombinants with the exogenous p27 marker underwent efficient shedding into eggs and the three recombinants with the endogenous p27° marker did not.
Example 3 Construction, Testing and Suggested Field Protocol for Use of A Vaccine for Subgroup A Avian Leukosis Viruses
A. Vaccine Construction
The restriction endonuclease fragment bounded by the Xhol site at bp—630 and bp-—5260 of RAV-0 proviral DNA was substituted for the comparable fragment in RAV-1 proviral DNA. Three such con¬ structions were cloned in a derivative of the plasmid pBR322. Two of these constructions, des¬ ignated Worcester Foundation 171 and 172 (WF171 and WF172) , were transfected into turkey cells to produce a virus stock. The recovered virus has most of the gag and all of the pol sequences of the benign virus RAV-0 and the env and LTR sequences of the subgroup A avian leukosis virus RAV-1. The virus recovered from WF171 and WF172 grows well in cultured fibroblasts. WF82 includes a virus attenu¬ ated by the substitution of the 3' end and LTRs of RAV-0 for the comparable sequences of RAV-1. It is useful for testing the efficacy of viruses contain¬ ing the U-j sequences of an endogenous virus (RAV-0) as opposed to an exogenous virus (RAV-1) for vaccine production.
B. Testing of the Vaccine Virus - Production of Neutralizing Sera
Production of neutralizing sera in response to infection with RAV-1 (an exogenous ALV of subgroup A); virus recovered from WF 71 and WF172; or virus recovered from WF82 was determined. As described above, virus recovered from WF171 and WF172 has most of the gag and all of the pol sequences of the benign virus RAV-0 and the env and LTR sequences of the exogenous subgroup A RAV-1. Virus recovered from WF82 has the 3' end and LTRs of RAV-0 substituted for the comparable sequences of RAV-1. Approximately 1 x 10 infectious units (i.v.) of RAV-1 or of virus recovered from WF171 or WF172 were inoculated into the breast muscle of 4-6-week-old and 14-week-old K28 chickens. Production of neutralizing antibodies (antibodies that neutralize subgroup A ALV infection) was determined in sera from these chickens at 2 weeks and 4 weeks (and for RAV-1 inoculated chickens, also at 3 months) after inoculation. Results of these tests are shown in Table 1; results are based on data from 3-5 chickens per group. Titers of neutralizing activity are given as the logarithm of the dilution which inactivated at least 200 focus forming units (ffu) of RSV(RAV-l). NT in the Table represents not tested; NNA represents no neutraliz¬ ing activity.
Approximately 1 x 10 or 1 x 10 i.u. of virus recovered from WF171, WF172 or WF82 were inoculated into the breast muscle of 10-week-old and 18-week-old K28 chickens. Production of neutralizing antibodies was determined in the sera from these chickens at 2 weeks and 4 weeks after inoculation. Results of these tests are shown in
Table 2; results are based on data from 1-4 chickens per group. Titers of neutralizing activity are expressed as described above.
The data from both these series of tests demonstrate that the viruses used (those recovered from WF171 and WF172) elicited a strong immune response in the inoculated chickens. The immune response was equivalent to that elicited by the exogenous RAV-1. In addition, these tests indicate that only small quantities of medium harvested from cultures infected with virus recovered from WF171 and WF172 are needed to inoculate chickens; that is, 1 milliliter of such medium (diluted 1:100) is sufficient to inoculate 1,000 chickens.
TABLE 1
Production of Neutralizing Sera in Response to Infection with Virus Recovered from WF171 and WF172
Titer of Neutralizing Activity for RSV (RAV-'l) at Different Times After Inoculation
4-6 weeks 14 weeks
2wk 4wk 3mo 8mo 2wk 4wk 3mo
Virus i.u.
RAV-1 106 2 3 3 NT NT NT
WF171 106 2 3-4 2-3 3-4
WF172 106 2 3-4 2-3 3-4 uninfected NT NNA NT NNA
TABLE 2 Production of Neutralizing Sera in Response to Infection with Virus Recovered from WF171, WF172 and WF82
Titer of Neutralizing Activity for RSV (RAV-1) at Different Times After Inoculation
10 weeks 18 weeks
2wk 4wk 3mo 2wk 4wk 3mo
10" 2 3 NNA 2-3
WF172 10' 1-2 3 2 3
10- 1-2 3 NNA 3
WF82 10 NNA NNA-2 NNA NNA-1 uninfected NNA NNA NNA NNA
In addition, viruses were inoculated in the breast muscle of K28 chickens of the indicated ages. Between 2 and 4 chickens were in each test group. Presence of neutralizing antibody in yolks of eggs laid by the inoculated hens'was determined. Titers of neutralizing sera were obtained in assays on one egg. In cases where assays were performed on more than one egg from a hen, the results were similar. Results are shown in Table 3. Titers of neutraliz¬ ing activity are the logarythim of the dilution of sera which inactivated at least 200 ffu of RSV(RAV-l) .
TABLE 3
Neutralizing Antibody in Yolks of Eggs Laid by Hens Inoculated with Virus Recovered from the WF170s
Age at which neutralizing activity was determined
Age at 5 months 8 months
Virus Inoculation yolk albumen yolk albumen
Test 1
RAV-1 4 wks NT NT 3 NNA uninfected NNA NNA
Test 2
WF171 14 wks 2-4 NNA
WF172 14 wks 2-4 NNA
C. Suggested Field Protocol for Use of Vaccine Viruses
The procedure for the use of virus recovered from WF171 and WF172 as a vaccine will be as follows:
1. Eggs to be hatched to establish a breeding population of hens will be screened to identify those which contain virus in their albumen. All eggs containing virus will be discarded. 2. Chicks hatched from virus-free eggs will be raised apart from other chickens.
3. At the time these chicks reach immune competence they will be vaccinated with virus recovered from WF171 or WF172.
After the initial year of vaccination, step 1 will no longer be necessary in the erradication program. Vaccination with virus recovered from WF171 or WF172 eliminates the Achilles heel of protocols now being tested by others - the re-establishment of congen- ital infections by the virus being used as a vac¬ cine. See deBoer, G.F. et al. , The control of lymphoid leukosis in a flock White Plymouth Rock chickens. The Veterinary Quarterly, 1.:23-28 (1979); deBoer, G.F. et al. , Horizontal transmission of lymphoid leukosis virus, influence of age, maternal antibodies and degree of contact exposure, Avian Pathology, 10:343-358 (1981).
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experi¬ mentation, many equivalents to the specific embodi¬ ments of the invention descϋbed herein. Such equivalents are intended to be encompassed by the following claims.
Claims
1. RNA comprising gag sequences of an endogenous retrovirus and sequences which encode antigens of at least one exogenous retrovirus.
2. RNA of Claim 1 in which the endogenous retrovirus and the exogenous retrovirus are avian retroviruses.
3. RNA comprising gag sequences of an endogenous avian leukosis virus and sequences which encode " antigens of at least one exogenous avian leukosis virus.
4. DNA comprising gag sequences of an endogenous retrovirus and sequences which encode antigens of at least one exogenous retrovirus.
5. A vaccine including the DNA of Claim 4.
6. DNA of Claim 4 in which the endogenous retrovirus and the exogenous retrovirus are avian retroviruses.
7. A vaccine including the DNA of Claim 6.
8. DNA comprising gag sequences of an endogenous avian leukosis virus and sequences which encode antigens of at least one exogenous avian leukosis virus.
9. A vaccine including the DNA of Claim 8.
-33-
10. A constructed retrovirus having nucleic acid sequences comprising gag sequences of an endogenous retrovirus and sequences which encode antigens of at least one exogenous
5- retrovirus.
11. A vaccine including the retrovirus of Claim 10.
12. A retrovirus of Claim 10 in which the endogenous retrovirus and the exogenous retrovirus are avian retroviruses.
i0 13. A vaccine including the retrovirus of Claim 12.
14. A constructed retrovirus having nucleic acid sequences comprising gag sequences of an endogenous avian leukosis virus and sequences which encode antigens of at least one exogenous
15 avian leukosis virus.
15. A vaccine including the retrovirus of Claim 14.
16. A method of making DNA comprising gag sequences of an endogenous retrovirus and sequences which encode antigens of at least one exogenous
20' retrovirus, comprising the steps of: a. producing DNA sequences comprising gag sequences of an endogenous retrovirus and DNA sequences which encode antigens of at least one exogenous retrovirus; 5" b. linking the DNA sequences to encode an RNA that can undergo a retroviral life cycle.
17. A method of Claim 16 in which the endogenous retrovirus and the exogenous retrovirus are avian retroviruses.
18. A method of making DNA' comprising gag sequences of an endogenous avian leukosis virus and sequences which encode antigens of at least one exogenous avian leukosis virus, comprising the steps of: a. producing DNA sequences comprising gag sequences of an endogenous avian leukosis virus and DNA sequences which encode antigens of at least one exogenous avian leukosis virus; and b. linking the DNA sequences to encode an RNA that can undergo a retroviral life cycle.
19. A method of making a retrovirus having nucleic acid sequences comprising gag sequences of an endogenous retrovirus and sequences which encode antigens of at least one exogenous retrovirus, comprising the steps of: a. producing DNA sequences comprising gag sequences of an endogenous retrovirus and DNA sequences which encode antigens of at least one exogenous retrovirus; b. linking the DNA sequences to encode an RNA that can undergo a retroviral life cycle; c. transfecting cells with the DNA; and d. maintaining conditions suitable for the production of virus.
20. A method of Claim 19 in which the endogenous retrovirus and the exogenous retrovirus are avian retroviruses.
21. A method of making a retrovirus having nucleic acid sequences comprising gag sequences of an endogenous avian leukosis virus and sequences which encode antigens of at least one exogenous avian leukosis virus, comprising the steps of: a. producing DNA sequences comprising gag sequences of an endogenous avian leukosis virus and DNA sequences which encode, antigens of at least one exogenous avian leukosis virus; b. linking the DNA sequences to encode an RNA that can undergo a retroviral life cycle; c. transfecting cells with the DNA; and d. maintaining conditions suitable for the production of virus.
22. DNA comprising cis-acting signals essential for an RNA transcript of the DNA to undergo a retroviral life cycle and sequences which encode antigens of at least one virus other than a retrovirus.
23. DNA of Claim 22 in which the cis-acting signals are essential for an RNA transcript to undergo an avian retroviral life cycle.
24. DNA comprising cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle and sequences which encode antigens of at least one virus other than a retrovirus.
25. A vaccine including 1) DNA comprising cis-acting signals essential for an RNA transcript of the DNA to undergo a retroviral life cycle and sequences which encode antigens ° of at least one virus other than a retrovirus; and 2) DNA comprising gag sequences of an endogenous retrovirus and sequences which encode host range of an exogenous retrovirus.
26. A vaccine of claim 25 in which retroviral 5 sequences are avian retroviral sequences.
27. A vaccine including 1) DNA comprising cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle and sequences which 0 encode antigens of at least one virus other than a retrovirus; and 2) DNA comprising gag sequences of an endogenous avian leukosis virus and sequences which encode host range of an exogenous avian leukosis virus.
5 28. A constructed retrovirus having nucleic acid sequences which encode cis-acting signals essential for an RNA transcript of the DNA to undergo a retroviral life cycle and sequences which encode antigens of at least one virus 0 other than a retrovirus.
29. A constructed retrovirus of Claim 28 in which the retroviral sequences are avian retroviral sequences.
30. A constructed retrovirus having nucleic acid 5 sequences which encode cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle and sequences which encode antigens of at least one virus other than a retrovirus.
10. 31. A vaccine including: 1) a constructed retrovirus having nucleic acid sequences which encode cis-acting signals essential for an RNA transcript of the DNA to undergo a retroviral life cycle and sequences which encode antigens
15. of at least one virus other than a retrovirus and; 2) a constructed retrovirus having nucleic acid sequences comprising gag sequences of an endogenous retrovirus and sequences which encode host range, of an exogenous retrovirus.
2Q- 32. A vaccine of Claim 31 in which the retroviral sequences are avian retroviral sequences.
33. A vaccine including: 1) a constructed retrovirus having nucleic acid sequences which encode cis-acting sequences essential for an 25- RNA transcript of the DNA to undergo an avian leukosis virus life cycle and sequences which encode antigens of at least one virus other than a retrovirus and; 2) a constructed retrovirus having nucleic acid sequences
comprising gag sequences of an endogenous avian leukosis virus and sequences which encode host range of an exogenous avian leukosis virus.
34. A method of constructing DNA comprising cis-acting signals essential for an RNA transcript of the DNA to undergo a retroviral life cycle and sequences which encode antigens of at least one virus other than a retrovirus, comprising the steps of: a. producing DNA sequences comprising cis-acting signals essential for RNA to undergo a retroviral life cycle and sequences which encode antigens of at least one virus other than a retrovirus; and b. linking the DNA sequences to encode an RNA that can undergo a retroviral life cycle.
35. A method of Claim 34 in which the retroviral sequences are avian retroviral sequences.
36. A method of constructing DNA comprising cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle and sequences which encode antigens of at least one virus other than a retrovirus, comprising the steps of: a. producing DNA sequences comprising cis-acting signals essential for RNA to undergo an leukosis virus life cycle and sequences which encode antigens of at least one virus other than a retrovirus; and
b. linking the DNA sequences to encode an RNA that can undergo an avian leukosis virus life cycle.
37. A method of constructing a retrovirus having nucleic acid sequences which encode cis-acting signals essential for an RNA transcript of the DNA to undergo a retroviral life cycle and sequences which encode antigens of at least one virus other than a retrovirus, comprising the steps of: a. producing DNA sequences comprising cis-acting signals essential for RNA to undergo a retroviral life cycle and sequences which encode antigens of at least one virus other than a retrovirus; b. linking the DNA sequences to encode an RNA that can undergo a retroviral life cycle. σ. transfecting cells with the DNA; and d. maintaining conditions suitable for the production of virus.
38. A method of Claim 37 in which the retroviral sequences are avian retroviral sequences.
39. A method of constructing a retrovirus having nucleic acid sequences which encode cis-acting signals essential for an RNA transcript of tire
DNA to undergo an avian leukosis virus life cycle and sequences which encode antigens of at least one virus other than a retrovirus, comprising the steps of:
a. producing DNA sequences comprising cis-acting signals essential for RNA to undergo an avian leukosis virus life cycle- and sequences which encode antigens of at least one virus other than a retrovirus; b. linking the DNA sequences to encode an RNA that can undergo an avian leukosis virus life cycle; c. transfecting cells with.the DNA; and d. maintaining conditions suitable for the production of virus.
40. DNA comprising gag sequences of an exogenous avian leukosis virus; sequences which encode host range of an exogenous avian leukosis virus; and pol sequences of an endogenous avian leukosis virus.
41. A constructed retrovirus having gag sequences of an exogenous avian leukosis virus; sequences which encode the host range of an exogenous avian leukosis virus; and pol sequences of an endogenous avian leukosis virus.
42. DNA comprising cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle; DNA sequences that control the production of an egg white protein; and DNA sequences that encode at least one nonviral protein.
43. A constructed retrovirus having cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle; DNA sequences that control the production of an egg white protein; and DNA sequences that encode at least one nonviral protein.
44. A stock including: 1) a constructed retrovirus having gag sequences of an exogenous avian leukosis virus; sequences which encode host range of an exogenous avian leukosis virus; and pol sequences of an endogenous avian leukosis virus; and 2) a constructed retrovirus having cis-acting signals essential for an RNA transcript of DNA to undergo an avian leukosis virus life cycle; DNA sequences that control the production of an egg white protein; and DNA sequences that encode at least one nonviral protein.
45. A method of making DNA comprising gag sequences of an exogenous avian leukosis virus; sequences which encode host range of an exogenous avian leukosis virus and pol sequences of an endogenous avian leukosis virus, comprising the steps of: a. producing DNA sequences comprising gag sequences of an exogenous avian leukosis virus; sequences which encode host range of an exogenous avian leukosis virus; and pol sequences of an endogenous avian leukosis virus; and
b. linking the DNA sequences to encode an RNA that can undergo an avian leukosis virus life cycle.
46. A method of making an avian leukosis virus having gag sequences of an exogenous avian leukosis virus; sequences which encode host range of an exogenous avian leukosis virus; and pol sequences of an endogenous avian leukosis virus, comprising the steps of: a. producing DNA sequences comprising gag sequences of an exogenous avian leukosis virus; sequences which encode the host range of an exogenous avian leukosis virus; and pol sequences of an endogenous avian leukosis virus; b. linking the DNA sequences to encode an RNA that can undergo an avian leukosis virus life cycle; c. transfecting cells with the DNA; and d. maintaining conditions suitable for the production of virus.
47. A method of making DNA comprising cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle; DNA sequences that control the production of an egg white protein; and DNA sequences that encode at least one nonviral protein, comprising the steps of: a. producing DNA sequences comprising cis-acting signals essential for an RNA transcript of the DNA to undergo an avian
leukosis virus life cycle; DNA sequences that control the production of an egg white protein; and DNA sequences that encode at least one nonviral protein; and b. linking the DNA sequences to encode an RNA that can undergo an avian leukosis virus life cycle.
48. A method of making an avian leukosis virus having cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle; DNA sequences that control the production of an egg white protein; and DNA sequences that encode at least one nonviral protein, comprising the steps of: a. producing DNA sequences comprising cis-acting signals essential for an RNA transcript of the DNA to undergo an avian leukosis virus life cycle; DNA sequences that control the production of an egg white protein; and DNA sequences that encode at least one nonviral protein; and b. linking the DNA sequences to encode an RNA that can undergo an avian leukosis virus life cycle; c. transfecting cells with the DNA; and d. maintaining conditions suitable for the production of virus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63272384A | 1984-07-20 | 1984-07-20 | |
US632,723 | 1984-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1986000930A1 true WO1986000930A1 (en) | 1986-02-13 |
Family
ID=24536672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1985/001352 WO1986000930A1 (en) | 1984-07-20 | 1985-07-18 | Retroviral vaccines and vectors and methods for their construction |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0188574A1 (en) |
IL (1) | IL75927A0 (en) |
WO (1) | WO1986000930A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3711016A1 (en) * | 1986-04-04 | 1987-10-08 | Hoffmann La Roche | EXPRESSION AND CLEANING OF A HTLV-III GAG / ENV FUSION PROTEIN |
WO1993019183A1 (en) * | 1992-03-23 | 1993-09-30 | University Of Massachusetts Medical Center | Immunization by inoculatioon of dna transcription unit |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US5665587A (en) * | 1989-06-26 | 1997-09-09 | Novo Nordisk A/S | Modified subtilisins and detergent compositions containing same |
US5691177A (en) * | 1988-03-21 | 1997-11-25 | Guber; Harry E. | Recombinant retroviruses expressing a protein that converts a pro-drug into a cytotoxic agent |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5856185A (en) * | 1988-03-21 | 1999-01-05 | Chiron Corporation | Method for making reflection defective retroviral vectors for infecting human cells |
US5874077A (en) * | 1989-10-24 | 1999-02-23 | Chiron Corporation | Human til cells expressing recombinant TNF prohormone |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5997859A (en) * | 1988-03-21 | 1999-12-07 | Chiron Corporation | Method for treating a metastatic carcinoma using a conditionally lethal gene |
US6165993A (en) * | 1992-03-23 | 2000-12-26 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US6197755B1 (en) | 1994-04-01 | 2001-03-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US6413942B1 (en) | 1989-03-21 | 2002-07-02 | Vical, Inc. | Methods of delivering a physiologically active polypeptide to a mammal |
US6531307B1 (en) | 1992-10-22 | 2003-03-11 | Chiron Corporation | Adenoviral vectors encoding a cytokine and a conditionally lethal gene |
US6569679B1 (en) | 1988-03-21 | 2003-05-27 | Chiron Corporation | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6710035B2 (en) | 1989-03-21 | 2004-03-23 | Vical Incorporated | Generation of an immune response to a pathogen |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US7358234B2 (en) | 1989-11-16 | 2008-04-15 | Duke University | Induction of a protective immune response through microprojectiles coated with a DNA sequence encoding an immunogenic protein |
EP1026253B2 (en) † | 1989-03-21 | 2012-12-19 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
RU2621146C1 (en) * | 2016-09-23 | 2017-05-31 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации" (ФГБНУ "НИВИ НЗ России") | Prevention method of postnatal infection by bovine leukosis virus of the young bovine stock |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
-
1985
- 1985-07-18 WO PCT/US1985/001352 patent/WO1986000930A1/en unknown
- 1985-07-18 EP EP85903758A patent/EP0188574A1/en not_active Withdrawn
- 1985-07-26 IL IL75927A patent/IL75927A0/en unknown
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Volume 98, part 23, 6 June 1983, Columbus, Ohio, (US) H.L. ROBINSON et al.: "Cancer Induction by Insertional Mutagenesis: the Role of Viral Genes in Avian Leukosis Virus Induced Cancers", see page 160, Abstract Nr. 192577m & Prog. Clin. Biol. Res. 1983, 119, 27-42 * |
Journal of Virology, Volume 33, Nr. 1, January 1980 P.N. TSICHLIS et al.: "Recombinants between Endogenous and Exogenous Avian Tumor Viruses: Role of the C Region and other Portions of the Genome in the Control of Replication and Transformation", pages 238-249, see the whole document * |
Science, Volume 225, 27 July 1984, H.L. ROBINSON et al.: "New Findings on the Congenital Transmission of Avian Leukosis Virus", pages 417-419, see the whole document * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT400442B (en) * | 1986-04-04 | 1995-12-27 | Hoffmann La Roche | METHOD FOR RECOMBINANTLY PRODUCING A PROTEIN |
US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
DE3744827C2 (en) * | 1986-04-04 | 1990-08-09 | F. Hoffmann-La Roche Ag, Basel, Ch | |
DE3744825C2 (en) * | 1986-04-04 | 1990-10-25 | F. Hoffmann-La Roche Ag, Basel, Ch | |
DE3711016A1 (en) * | 1986-04-04 | 1987-10-08 | Hoffmann La Roche | EXPRESSION AND CLEANING OF A HTLV-III GAG / ENV FUSION PROTEIN |
US5997859A (en) * | 1988-03-21 | 1999-12-07 | Chiron Corporation | Method for treating a metastatic carcinoma using a conditionally lethal gene |
US6569679B1 (en) | 1988-03-21 | 2003-05-27 | Chiron Corporation | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene |
US6241982B1 (en) | 1988-03-21 | 2001-06-05 | Chiron Corporation | Method for treating brain cancer with a conditionally lethal gene |
US5691177A (en) * | 1988-03-21 | 1997-11-25 | Guber; Harry E. | Recombinant retroviruses expressing a protein that converts a pro-drug into a cytotoxic agent |
US5716613A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5830458A (en) * | 1988-03-21 | 1998-11-03 | Gruber; Harry E. | Method for destroying a diseased human cell |
US6410326B1 (en) * | 1988-03-21 | 2002-06-25 | Chiron Corporation | Method for inhibiting human tumor cells |
US5851529A (en) * | 1988-03-21 | 1998-12-22 | Guber; Harry E. | Recombinant retroviruses |
US5856185A (en) * | 1988-03-21 | 1999-01-05 | Chiron Corporation | Method for making reflection defective retroviral vectors for infecting human cells |
US6495349B1 (en) | 1988-03-21 | 2002-12-17 | Harry E. Gruber | Chimeric gene constructs |
US5888502A (en) * | 1988-03-21 | 1999-03-30 | Guber; Harry E. | Recombinant retroviruses |
US6133029A (en) * | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
EP1026253B2 (en) † | 1989-03-21 | 2012-12-19 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US6710035B2 (en) | 1989-03-21 | 2004-03-23 | Vical Incorporated | Generation of an immune response to a pathogen |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US6413942B1 (en) | 1989-03-21 | 2002-07-02 | Vical, Inc. | Methods of delivering a physiologically active polypeptide to a mammal |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US7250404B2 (en) | 1989-03-21 | 2007-07-31 | Vical Incorporated | Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response |
US7189553B2 (en) | 1989-06-26 | 2007-03-13 | Novozymes A/S | Modified subtilisins and detergent, compositions containing same |
US6197567B1 (en) | 1989-06-26 | 2001-03-06 | Novo Nordisk A/S | Modified subtilisins and detergent compositions containing same |
US5665587A (en) * | 1989-06-26 | 1997-09-09 | Novo Nordisk A/S | Modified subtilisins and detergent compositions containing same |
US5874077A (en) * | 1989-10-24 | 1999-02-23 | Chiron Corporation | Human til cells expressing recombinant TNF prohormone |
US7358234B2 (en) | 1989-11-16 | 2008-04-15 | Duke University | Induction of a protective immune response through microprojectiles coated with a DNA sequence encoding an immunogenic protein |
US7449449B2 (en) | 1989-11-16 | 2008-11-11 | Duke University | Particle-mediated transformation of vertebrate tissue cells |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
WO1993019183A1 (en) * | 1992-03-23 | 1993-09-30 | University Of Massachusetts Medical Center | Immunization by inoculatioon of dna transcription unit |
US6165993A (en) * | 1992-03-23 | 2000-12-26 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US7850956B2 (en) | 1992-03-23 | 2010-12-14 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US6841381B1 (en) | 1992-03-23 | 2005-01-11 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US6531307B1 (en) | 1992-10-22 | 2003-03-11 | Chiron Corporation | Adenoviral vectors encoding a cytokine and a conditionally lethal gene |
US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US6197755B1 (en) | 1994-04-01 | 2001-03-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
US7202227B2 (en) | 1994-09-28 | 2007-04-10 | Wyeth | Multifunctional molecular complexes for gene transfer to cells |
US6379965B1 (en) | 1994-09-28 | 2002-04-30 | American Home Products Corporation | Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having an endosome disruption agent |
US6127170A (en) * | 1994-09-28 | 2000-10-03 | American Home Products Corporation | Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having a endosome disruption agent |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
RU2621146C1 (en) * | 2016-09-23 | 2017-05-31 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации" (ФГБНУ "НИВИ НЗ России") | Prevention method of postnatal infection by bovine leukosis virus of the young bovine stock |
Also Published As
Publication number | Publication date |
---|---|
IL75927A0 (en) | 1985-12-31 |
EP0188574A1 (en) | 1986-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1986000930A1 (en) | Retroviral vaccines and vectors and methods for their construction | |
Salter et al. | Gene insertion into the chicken germ line by retroviruses | |
Venugopal | Avian leukosis virus subgroup J: a rapidly evolving group of oncogenic retroviruses | |
Crittenden et al. | Influence of endogenous viral (ev) gene expression and strain of exogenous avian leukosis virus (ALV) on mortality and ALV infection and shedding in chickens | |
US4997763A (en) | Vectors for gene insertion into avian germ line | |
Johnson et al. | Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines | |
CN102405058B (en) | For restructuring avian herpetoviruses carrier and the vaccine of immunity inoculation aquatic bird species | |
Arshad et al. | Tissue tropism of the HPRS-103 strain of J subgroup avian leukosis virus and of a derivative acutely transforming virus | |
Fadly | Isolation and identification of avian leukosis viruses: a review | |
Steffen et al. | Evidence for the Asiatic origin of endogenous AKR-type murine leukemia proviruses | |
EP0473210A2 (en) | Recombinant Marek's disease virus | |
WO1990011355A1 (en) | Introducing an exogenous gene into birds | |
CRITTENDEN et al. | A transgene, alv 6, that expresses the envelope of subgroup a avian leukosis virus reduces the rate of congenital transmission of a field strain of avian leukosis virus | |
EP0424044A1 (en) | Transgenic fowl expressing bovine growth hormone | |
US20050022260A1 (en) | Method of efficiently constructing transgenic birds and transgenic birds thus obtained | |
Fadly | Avian retroviruses | |
SMITH et al. | Interactions Between Endogenous Virus Loci ev 6 and ev 21.: 1. Immune Response to Exogenous Avian Leukosis Virus Infection | |
RU2329060C2 (en) | Method of obtaining continuous cell line and application of continuous cell line | |
EP0424027A1 (en) | Vectors for generating transgenic fowl | |
Hunt et al. | A genetically engineered cell line resistant to subgroup J avian leukosis virus infection (C/J) | |
Smith et al. | Selective shedding and congenital transmission of endogenous avian leukosis viruses | |
Frossard | Retroviridae | |
JP4037273B2 (en) | Repolipox based vector vaccine | |
JP2905483B2 (en) | Attenuated herpes virus and herpes virus containing exogenous DNA | |
Zavala et al. | Sarcomas and myelocytomas induced by a retrovirus related to myeloblastosis-associated virus type 1 in White Leghorn egg layer chickens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |